Ketorolac (Toradol) Injection in a 9-Year-Old Child
Ketorolac is NOT FDA-approved for use in children under 17 years of age, and the FDA drug label explicitly states that "safety and effectiveness in pediatric patients below the age of 17 years have not been established." 1
Critical FDA Contraindication
The FDA drug label is unequivocal: ketorolac tromethamine is not indicated for use in pediatric patients 1. This represents the highest level of regulatory guidance and must be prioritized in clinical decision-making.
Off-Label Use Context
Despite the FDA contraindication, ketorolac has been used off-label in pediatric populations, particularly in postoperative settings. However, this practice exists in a regulatory gray zone and carries medicolegal implications.
Dosing Information from Research Literature (Off-Label)
If ketorolac is being considered off-label despite FDA guidance, research suggests:
- Standard dose: 0.5 mg/kg IV as a single dose 2, 3
- Dosing interval: Every 6 hours if multiple doses needed 2
- Maximum daily dose: 90 mg 2
- Maximum duration: 48 hours 2
- Age restriction: Not recommended for infants <1 year 2
Recent evidence suggests lower doses may be safer: A 2024 meta-analysis found that 0.5 mg/kg ketorolac significantly reduces the risk of primary bleeding compared to 0.9-1.0 mg/kg doses, while still providing adequate pain control 4.
Pharmacokinetic Considerations
Children have different ketorolac pharmacokinetics compared to adults 1, 3:
- Higher volume of distribution (approximately 2-fold increase)
- Higher plasma clearance (due to lower protein binding)
- Similar elimination half-life to adults (5-6 hours)
A 2002 study demonstrated that body weight-normalized pharmacokinetic variables in children aged 1-16 years were similar to adult values, with a single 0.5 mg/kg dose maintaining therapeutic plasma concentrations for approximately 6 hours 3.
Safety Profile and Risks
Bleeding Risk
This is the most critical safety concern. Ketorolac is associated with:
- Increased risk of primary operative bleeding requiring surgical control, particularly at higher doses (0.9-1.0 mg/kg) 4
- The 2024 meta-analysis of 11,729 pediatric tonsillectomy patients showed 0.5 mg/kg doses did NOT increase primary operative bleeding risk, while 0.9-1.0 mg/kg doses significantly increased bleeding (OR = 4.07) 4
Renal Toxicity
Ketorolac carries risk of acute kidney injury, particularly in 5:
- Infants <6 months (highest risk)
- Patients with preexisting renal dysfunction
- Concomitant aspirin use
- Single-ventricle cardiac palliation patients
Avoid in these high-risk populations.
Gastrointestinal Effects
Standard NSAID risks apply, though less commonly reported in short-term pediatric use 2, 6.
Clinical Evidence Quality
The 2021 AATS Congenital Cardiac Surgery consensus document notes that while ketorolac shows benefit in reducing pain and opioid requirements in children undergoing various surgical procedures, "a Cochrane review of postoperative pain management in children with ketorolac showed that the quality of evidence for its use in treating postoperative pain was very low" 5.
Practical Recommendations
Given the FDA contraindication, alternative analgesics should be strongly considered first:
- Ibuprofen (10 mg/kg PO/IV every 8 hours) 7
- Acetaminophen (15 mg/kg IV loading dose, then 10-15 mg/kg every 6 hours) 7
- Combination therapy with acetaminophen + ibuprofen
- Opioid analgesics if pain severity warrants
If Ketorolac Must Be Used Off-Label
Only after careful risk-benefit analysis and informed consent:
- Dose: 0.5 mg/kg IV (NOT 0.9-1.0 mg/kg)
- Maximum single dose: 15-30 mg (recent evidence suggests 15 mg ceiling may be adequate) 8
- Duration: ≤48 hours
- Screen for contraindications: bleeding disorders, renal dysfunction, aspirin allergy, active GI disease
- Monitor: renal function, bleeding parameters
- Document: rationale for off-label use and informed consent discussion
Common Pitfalls
- Assuming pediatric dosing mirrors adult dosing - it does not due to pharmacokinetic differences
- Using doses >0.5 mg/kg - increases bleeding risk without additional analgesic benefit 4
- Prolonged use beyond 48 hours - increases risk of renal and GI complications
- Failing to recognize FDA contraindication - creates medicolegal exposure
- Using in infants <1 year - particularly high risk population 2